Structure-activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobacterium tuberculosis. I. Modifications to the adenine moiety

Biochemical Pharmacology

Volumn 71, Issue 12, 2006, Pages 1671-1682

  Long, Mary C ^a   Parker, William B ^b  

^a University of Alabama at Birmingham   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Adenosine kinase; Methyl adenosine; Mycobacterium tuberculosis; nucleoside analogs; Purine salvage; Structure activity relationship

Indexed keywords

1 (4 FLUOROBENZYLOXY)ADENOSINE; 2 (1 ETHYN 1 YL)ADENOSINE; 2 AMINOADENOSINE; 2 AZA ADENOSINE; 2 AZIDO ADENOSINE; 2 BROMOADENOSINE; 2 CHLOROADENOSINE; 2 ETHYLADENOSINE; 2 FLUORO 3 DEAZA ADENOSINE; 2 FLUOROADENOSINE; 2 METHOXYADENOSINE; 2 METHYLADENOSINE; 2 TRIFLUOROMETHYLADENOSINE; 3 DEAZA ADENOSINE; 6 CHLOROPURINE RIBONUCLEOSIDE; 6 CYCLOPENTYLOXY PURINE RIBOSIDE; 8 AZA 9 DEAZA ADENOSINE; ADENOSINE 1 OXIDE; ADENOSINE KINASE; ADENOSINE KINASE INHIBITOR; ISOGUANOSINE; N1 BENZYLADENOSINE; N1 ETHYLADENOSINE; N1 METHYLADENOSINE; N1 OXY 2' DEOXYADENOSINE; N1 OXY N6 METHYLADENOSINE; N6 AMINOADENOSINE; NUCLEOSIDE ANALOG; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CHEMICAL MODIFICATION; DRUG DESIGN; DRUG POTENCY; ENZYME INHIBITION; ENZYME SUBSTRATE; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ADENINE; ADENOSINE KINASE; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646513715     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.03.006     Document Type: Article

References (34)

1. Blumberg H.M., Michael K., Leonard J., and Jasmer R.M. Update on the treatment of tuberculosis and latent tuberculosis infection. J Am Med Assoc 293 (2005) 2776-2784
2. DeAngelis C.D., and Flanagin A. Tuberculosis-a global problem requiring a global solution. J Am Med Assoc 293 (2005) 2793-2794
3. Dye C., Watt C.J., Bleed B.M., Hosseini S.M., and Raviglione M.C. Evolution of tuberculosis control and prospect for reducing tuberculosis incidence, prevalence, and deaths globally. J Am Med Assoc 293 (2005) 2767-2775
4. Hampton T. TB drug research picks up the pace. J Am Med Assoc 293 (2005) 2707
5. Nettleman M.D. Multidrug-resistant tuberculosis news from the front. J Am Med Assoc 293 (2005) 2788-2790
6. Orme I. Search for new drugs for treatment of tuberculosis. Antimicrob Agents Chemother 45 (2001) 1943-1946
7. Barrow E.W., Westbrook L., Bansal N., Suling W.J., Maddry J.A., Parker W.B., et al. Antimycobacterial activity of 2-methyl-adenosine. J Antimicrob Chemother 52 (2003) 801-808
8. Parker W.B., Barrow E.W., Allan P.W., Shaddix S.C., Long M.C., Barrow W.W., et al. Metabolism of 2-methyladenosine in Mycobacterium tuberculosis. Tuberculosis 84 (2004) 327-336
9. Chen C.-K., Barrow E.W., Allan P.W., Bansal N., Maddry J.A., Suling W.J., et al. The metabolism of 2-methyladenosine in Mycobacterium smegmatis. Microbiology 148 (2002) 289-295
10. Long M.C., Escuyer V., and Parker W.B. Identification and characterization of a unique adenosine kinase from Mycobacterium tuberculosis. J Bacteriol 185 (2003) 6548-6555
11. Spychala J., Datta N.S., Takakbayashi K., Datta M., Fox I.H., Gribbin T., et al. Cloning of human adenosine kinase cDNA: sequencec similarity to microbial ribokianses and fructokinases. Proc Natl Acad Sci USA 93 (1996) 1232-1237
12. Wheeler P.R., and Ratledge C. Metabolism of Mycobacterium tuberculosis. In: Bloom B.R. (Ed). Tuberculosis pathogenesis, protection, and control (1994), ASM Press, Washington, DC 353-385
13. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998) 537-544
14. Wang Y., Long M.C., Ranganathan S., Escuyer V., Parker W.B., and Li R. Overexpression, purification and crystrallographic analysis of a unique adenosine kinase from Mycobacterium tuberculosis. Acta Crystallogr Sect F F61 (2005) 553-557
15. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
16. Iltzsch M.H., Uber S.S., Tankersley K.O., and el Kouni M.H. Structure-activity relationship for the binding of nucleoside ligands to adenosine kinase from Toxoplasma gondii. Biochem Pharmacol 49 (1995) 1501-1512
17. Miller R.L., Adamczyk D.L., and Miller W.H. Adenosine kinase from rabbit liver. I. Purification by affinity chromatography and properties. J Biol Chem 254 (1979) 2339-2345
18. Rais R.H., Al Safarjalani O.N., Yadav V., Guarcello V., Kirk M., Chu C.K., et al. 6-Benzylthioinosine analogues as subversive substrate of Toxoplasma gondii adenosine kinase: activities and selective toxicities. Biochem Pharmacol 69 (2005) 1409-1419
19. Schnebli H.P., Hill D.L., and Bennett Jr. L.L. Purification and properties of adenosine kinase from human tumor cells of type H. Ep. No. 2. J Biol Chem 242 (1967) 1997-2004
20. Bennett Jr. L.L., and Allan P.W. Metabolism and metabolic effects of 8-azainosine and 8-azaadenosine. Cancer Res 36 (1976) 3917-3923
21. Bennett Jr. L.L., Smithers D., Rose L.M., Adamson D.J., Shaddix S.C., and Thomas H.J. Metabolism and metabolic effects of 2-azahypoxanthine and 2-azaadenosine. Biochem Pharmacol 34 (1985) 1293-1304
22. Montgomery J.A., Laseter A.G., Shortnacy A.T., Clayton S.J., and Thomas H.J. Nucleosides of 2-azapurines. 7 H-Imidazo[4,5-d]-1,2,3-triazines. 2. J Med Chem 18 (1975) 564-567
23. Bennett Jr. L.L., Brockman R.W., Allan P.W., Rose L.M., and Shaddix S.C. Alterations in nucleotide pools induced by 3-deazaadenosine and related compounds. Role of adenylate deaminase. Biochem Pharmacol 37 (1988) 1233-1244
24. Carrasco L., and Vazquez D. Molecular bases for the action and selectivity of nucleoside antibiotics. Med Res Rev 4 (1984) 471-512
25. Cottam H.B., Wasson D.B., Shih H.C., Raychaudhuri A., Di Pasquale G., and Carson D.A. New adenosine kinase inhibitors with oral antiinflammatory activity: synthesis and biological evaluation. J Med Chem 36 (1993) 3424-3430
26. Henderson J.F., Paterson A.R., Caldwell I.C., Paul B., Chan M.C., and Lau K.F. Inhibitors of nucleoside and nucleotide metabolism. Cancer Chemother Rep 2 3 (1972) 71-85
27. Newby A.C. The interaction of inhibitors with adenosine metabolising enzymes in intact isolated cells. Biochem Pharmacol 30 (1981) 2611-2615
28. Suhadolnik R.J. Nucleoside antibiotics (1970), John Wiley & Sons
29. Willis R.C., Carson D.A., and Seegmiller J.E. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci USA 75 (1978) 3042-3044
30. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
31. Mathews I.I., Erion M.D., and Ealick S.E. Structure of human adenosine kinase at 1.5 A resolution. Biochemistry 37 (1998) 15607-15620
32. Schumacher M.A., Scott D.M., Mathews I.I., Ealick S.E., Roos D.S., Ullman B., et al. Crystal structures of Toxoplasma gondii adenosine kinase reveal a novel catalytic mechanism and prodrug binding. J Mol Biol 298 (2000) 875-893
33. Lin B.B., Hurley M.C., and Fox I.H. Regulation of adenosine kinase by adenosine analogs. Mol Pharmacol 34 (1988) 501-505
34. Yadav V., Chu C.K., Rais R.H., Al Safarjalani O.N., Guarcello V., Naguib F.N., et al. Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. J Med Chem 47 (2004) 1987-1996